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Objectives: Zilucoplan (complement C5 inhibitor) has profound effects on inhibiting acute lung injury post
COVID-19, and can promote lung repair mechanisms that lead to improvement in lung oxygenation
parameters. The purpose of this study is to investigate the efficacy and safety of Zilucoplan in improving
oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure.
Trial design: This is a phase 2 academic, prospective, 2:1 randomized, open-label, multi-center interventional study.
Participants: Adult patients (≥18y old) will be recruited at specialized COVID-19 units and ICUs at 9 Belgian hospitals.
The main eligibility criteria are as follows:
1) Inclusion criteria:
a. Recent (≥6 days and ≤16 days) SARS-CoV-2 infection.
b. Chest CT scan showing bilateral infiltrates within the last 2 days prior to randomisation.
c. Acute hypoxia (defined as PaO2/FiO2 below 350 mmHg or SpO2 below 93% on minimal 2 L/min supplemental
oxygen).
d. Signs of cytokine release syndrome characterized by either high serum ferritin, or high D-dimers, or high LDH or
deep lymphopenia or a combination of those.
2) Exclusion criteria:
e. Mechanical ventilation for more than 24 hours prior to randomisation.
f. Active bacterial or fungal infection.
g. History of meningococcal disease (due to the known high predisposition to invasive, often recurrent meningococcal
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infections of individuals deficient in components of the alternative and terminal complement pathways).
Intervention and comparator: Patients in the experimental arm will receive daily 32,4 mg Zilucoplan
subcutaneously and a daily IV infusion of 2g of the antibiotic ceftriaxone for 14 days (or until hospital
discharge, whichever comes first) in addition to standard of care. These patients will receive additional
prophylactic antibiotics until 14 days after the last Zilucoplan dose: hospitalized patients will receive a daily
IV infusion of 2g of ceftriaxone, discharged patients will switch to daily 500 mg of oral ciprofloxacin.
The control group will receive standard of care and a daily IV infusion of 2g of ceftriaxone for 1 week (or
until hospital discharge, whichever comes first), to control for the effects of antibiotics on the clinical course
of COVID-19.
Main outcomes: The primary endpoint is the improvement of oxygenation as measured by mean and/or
median change from pre-treatment (day 1) to post-treatment (day 6 and 15 or at discharge, whichever
comes first) in PaO2/FiO2 ratio, P(A-a)O2 gradient and a/A PO2 ratio.
(PAO2= Partial alveolar pressure of oxygen, PaO2=partial arterial pressure of oxygen, FiO2=Fraction of inspired
oxygen).
Randomisation: Patients will be randomized in a 2:1 ratio (Zilucoplan: control). Randomization will be done
using an Interactive Web Response System (REDCap).
Blinding (masking): In this open-label trial neither participants, caregivers, nor those assessing the
outcomes will be blinded to group assignment.
Numbers to be randomised (sample size): A total of 81 patients will be enrolled: 54 patients will be
randomized to the experimental arm and 27 patients to the control arm.
Trial Status: ZILU-COV protocol Version 4.0 (June 10 2020). Participant recruitment started on June 23 2020
and is ongoing. Given the uncertainty of the pandemic, it is difficult to predict the anticipated end date.
Trial registration: The trial was registered on Clinical Trials.gov on May 11th, 2020 (ClinicalTrials.gov
Identifier: NCT04382755) and on EudraCT (Identifier: 2020-002130-33).
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website
(Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has
been eliminated; this Letter serves as a summary of the key elements of the full protocol.
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